Jérôme Biollaz

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


265 publications

... | 1989 | 1988 | 1987 | 1986 | 1985 | 1984 | 1983 | 1982 | 1981 | 1980 | 1979 |
1989
 
Erreurs thérapeutiques fréquentes chez les personnes âgées
Steinhäuslin F., Biollaz J., 1989. Hospitalis, 59 (10) pp. 710-714.
[serval:BIB_BDF13AFFF0A4]
 
Influence of debrisoquin phenotype on the inducibility of propranolol metabolism.
Shaheen O., Biollaz J., Koshakji R.P., Wilkinson G.R., Wood A.J., 1989. Clinical Pharmacology and Therapeutics, 45 (4) pp. 439-443.
[DOI][WoS][Pmid][serval:BIB_61B7032FD7EA]
 
Influence of food and antacid administration on fluoride bioavailability from enteric-coated sodium fluoride tablets
Arnold P., Wermeille M., Chapuy M. C., Biollaz J., Grandjean E. M., Schelling J. L., Meunier P. J., 1989. Bone, 10 (6) pp. 401-7.
[DOI][WoS][Pmid][serval:BIB_FA4BB99EA3D2]
 
Influence of food and antacid administration on fluoride bioavailability from enteric-coated sodium fluoride tablets.
Arnold P., Wermeille M., Chapuy M.C., Biollaz J., Grandjean E.M., Schelling J.L., Meunier P.J., 1989. Bone, 10 (6) pp. 401-407.
[serval:BIB_2D481EEDD421]
 
Troubles électrolytiques d'origine médicamenteuse: aspects physiologiques et physiopathologiques
Steinhäuslin F., Biollaz J., 1989. Médecine et Hygiène, 47 (1791) pp. 1202-1213.
[URN][serval:BIB_219FFE32946F]
1988
 
Courbe dose-reponse et etude clinique preliminaire d'un laxatif, le lactitol. [Dose-response curve and preliminary clinical study of a laxative, lactilol]
Walder M., Buclin T., Biollaz J., Kitler M. E., Schelling J. L., 1988/12. Schweizerische Medizinische Wochenschrift, 118 (50) pp. 1925-7.
[WoS][Pmid][serval:BIB_6C0253EDD8AB]
Grand mal seizure after extradural morphine analgesia
Borgeat A., Biollaz J., Depierraz B., Neff R., 1988/05. British Journal of Anaesthesia, 60 (6) pp. 733-5.
[URN][DOI][WoS][Pmid][serval:BIB_8743E0EA0F98]
 
Traitement de l'insuffisance cardiaque par les vasodilatateurs. [The treatment of cardiac insufficiency with vasodilators]
Biollaz J., Munafo A., 1988/04. Schweizerische Medizinische Wochenschrift, 118 (17) pp. 616-20.
[WoS][Pmid][serval:BIB_94FC06AD6F0B]
 
Aldosterone and Urinary Lithium Excretion
Diezi J., Biollaz J., 1988. pp. 159-167 dans Johnson F.N. (eds.) Lithium an the Endocrine System, Karger.
[URN][serval:BIB_3977C6EB2F0C]
 
Facteur natriurétique auriculaire chez l'homme: implications physiopathologiques [Atrial natriuretic factor in man: physiopathological implications]
Biollaz J., Nussberger J., Waeber B., Brunner H.R., 1988. Schweizerische Rundschau für Medizin Praxis, 77 (24) pp. 669-672.
[Pmid][serval:BIB_67A44CFB9F49]
 
Hemodynamic, renal, and endocrine effects of 4-h infusions of human atrial natriuretic peptide in normal volunteers.
Bidiville J., Waeber G., Porchet M., Nussberger J., Biollaz J., Gomez H., Callahan L., Waeber B., Brunner H.R., 1988. Fundamental & clinical pharmacology, 2 (5) pp. 413-29. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_52EB2E10411B]
 
Hemofiltration clearance of flecainide in a patient with acute renal failure
Borgeat A., Biollaz J., Freymond B., Bayer-Berger M., Chiolero R., 1988. Intensive Care Medicine, 14 (3) pp. 236-7.
[DOI][WoS][Pmid][serval:BIB_2BB6202C2205]
 
Infusion of atrial natriuretic peptide to patients with congestive heart failure.
Goy J.J., Waeber B., Nussberger J., Bidiville J., Biollaz J., Nicod P., Mooser V., Kappenberger L., Brunner H.R., 1988. Journal of cardiovascular pharmacology, 12 (5) pp. 562-70. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_17A9E77D2107]
 
Lactitol: gastrointestinal absorption and effect on blood lactate in healthy volunteers and patients with cirrhosis.
Metzger J., Chollet C., Wermeille M., Biollaz J., Llull J.B., Lauterburg B.H., 1988. European Journal of Clinical Pharmacology, 35 (1) pp. 97-99. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E51BCA895665]
 
Les vasodilatateurs : tolérance et aspects pharmacocinétiques
Biollaz J., Buclin T., 1988. Der Informierte Arzt = Gazette médicale, 8 (4) pp. 81-82.
[URN][serval:BIB_B2581C7388E6]
Mechanism of Action of Vasodilating Agents
Biollaz J., Munafo A., Buclin T., 1988. pp. 275-288 dans Perret C., Vincent J.L. (eds.) Acute Heart Failure, Springer.
[serval:BIB_B6F468393909]
 
Tolerability and pharmacokinetics of L-648,051. A leukotriene D4-receptor antagonist, in healthy volunteers
Biollaz J., Stahl E., Hsieh J. Y., Distlerath L., Jaeger A., Leuenberger P., Schelling J. L., 1988. European Journal of Clinical Pharmacology, 33 (6) pp. 603-7.
[DOI][WoS][Pmid][serval:BIB_B10FF920C18A]
 
Tolerability and pharmacokinetics of L-648,051. A leukotriene D4-receptor antagonist, in healthy volunteers.
Biollaz J., Stahl E., Hsieh J.Y., Distlerath L., Jaeger A., Leuenberger P., Schelling J.L., 1988. European Journal of Clinical Pharmacology, 33 (6) pp. 603-607.
[Pmid][serval:BIB_3383696409A6]
1987
 
Posologie des medicaments chez le patient obese. [Posology of drugs in the obese patient]
Biollaz J., Schelling J. L., 1987/08. Therapeutische Umschau, 44 (8) pp. 601-6.
[WoS][Pmid][serval:BIB_6C3C491D6282]
 
Lack of angiotensin I accumulation after converting enzyme blockade by enalapril or lisinopril in man.
Nussberger J., Brunner D.B., Waeber B., Biollaz J., Brunner H.R., 1987/03. Clinical science, 72 (3) pp. 387-389. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E9836251C25C]
 
Clinical Pharmacology of two synthetic atrial natriuretic pepties
Biollaz J., Waeber B., Nussberger J., Brunner H.R., 1987. pp. 93-113 dans Glorioso N., Laragh J.H., Rappelli A. (eds.) Renovascular Hypertension : Pathophysiology, Diagnosis, and Treatment, Raven Press.
[URN][serval:BIB_9500DDE50089]
Effect of Atrial Natriuretic Peptide on Urinary Kallikrein in Normal Humans
Mimran A., Biollaz J., Nussberger J., Waeber B., Brunner H.R., 1987. pp. 287-289 dans Brenner B.M., Laragh J.H. (eds.) Biologically Active Atrial Peptides, Raven Press.
[URN][serval:BIB_2C7F16FB2297]
 
Effect of human atrial natriuretic factor on renal plasma flow
Bischof-Delaloye A., Bidiville J., Waeber B., Biollaz J., Gomez H., Delaloye B., Brunner H. R., 1987. Contributions to Nephrology, 56 pp. 12-7.
[Pmid][serval:BIB_CCBAF9449EB3]
 
Effets extra-rénaux du facteur natriurétique auriculaire [Extrarenal effects of the atrial natriuretic factor]
Biollaz J., Goy J.J., Nussberger J., Waeber B., Brunner H.R., 1987. Néphrologie, 8 (1) pp. 13-7. Peer-reviewed.
[WoS][Pmid][serval:BIB_A140A15BE9B4]
 
Expériences cliniques avec le facteur natriurétique auriculaire [Clinical experiences with atrial natriuretic factor]
Brunner H.R., Biollaz J., Waeber B., Nussberger J., 1987. Schweizerische medizinische Wochenschrift, 117 (49) pp. 1937-40. Peer-reviewed.
[WoS][Pmid][serval:BIB_AC22CDB0C5C4]
 
Human trials with atrial natriuretic peptides
Biollaz J., Waeber B., Nussberger J., Brunner H.R., 1987. pp. 250-258 dans Puschett J.B., Greenberg A. (eds.) 2nd International Conference on Diuretics, Diuretics II : chemistry, pharmacology, and clinical applications : proceedings.
[serval:BIB_C8B1242C565C]
 
Le choix des antiarythmiques cardiaques [Choice of cardiac antiarrhythmia agents].
Kappenberger L., Biollaz J., 1987. Therapeutische Umschau. Revue Thérapeutique, 44 (8) pp. 591-595.
[WoS][Pmid][serval:BIB_C1B8B4DF1953]
 
Pharmacokinetics of synthetic atrial natriuretic peptides in normal men.
Biollaz J., Callahan L.T., Nussberger J., Waeber B., Gomez H.J., Blaine E.H., Brunner H.R., 1987. Clinical Pharmacology and Therapeutics, 41 (6) pp. 671-677. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_23CA6AE7C186]
 
Site of the action of a synthetic atrial natriuretic peptide evaluated in humans.
Biollaz J., Bidiville J., Diézi J., Waeber B., Nussberger J., Brunner-Ferber F., Gomez H.J., Brunner H.R., 1987. Kidney International, 32 (4) pp. 537-546. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B65D518F86EC]
1986
 
Effect of oral triiodothyronine during amiodarone treatment for ventricular premature complexes.
Polikar R., Goy J.J., Schlapfer J., Lemarchand-Beraud T., Biollaz J., Magnenat P., Nicod P., 1986/11. American Journal of Cardiology, 58 (10) pp. 987-991.
[DOI][WoS][Pmid][serval:BIB_D4D1E58F73EF]
 
Enprostil, in contrast to cimetidine, does not inhibit propranolol metabolism
Reilly C. S., Biollaz J., Koshakji R. P., Wood A. J., 1986/07. Clinical Pharmacology and Therapeutics, 40 (1) pp. 37-41.
[DOI][WoS][Pmid][serval:BIB_DAEC5B08E30A]
 
Lithium infusion to study sodium handling in unanesthetized hypertensive rats
Biollaz J., Waeber B., Diezi J., Burnier M., Brunner H. R., 1986/02. Hypertension, 8 (2) pp. 117-21. Peer-reviewed.
[WoS][Pmid][serval:BIB_408F8470874C]
 
Atrial natriuretic peptides: reproducibility of renal effects and response of liver blood flow.
Biollaz J., Waeber B., Nussberger J., Porchet M., Brunner-Ferber F., Otterbein E.S., Gomez H.J., Brunner H.R., 1986. European journal of clinical pharmacology, 31 (1) pp. 1-8. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_043C32AE32F3]
 
Chronic treatment of hypertensive patients with converting enzyme inhibitors.
Nussberger J., Biollaz J., Waeber B., Brunner H.R., 1986. Journal of cardiovascular pharmacology, 8 (Suppl 1) pp. S20-5. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_417056A26A5D]
 
Clinical pharmacology of atrial natriuretic (3-28) eicosahexapeptide.
Biollaz J., Nussberger J., Waeber B., Brunner H.R., 1986. Journal of Hypertension. Supplement, 4 (2) pp. S101-108.
[WoS][Pmid][serval:BIB_B2C29C4B47D4]
 
Dose-dependent effect of atrial natriuretic peptide on blood pressure, heart rate, and skin blood flow of normal volunteers.
Bussien J.P., Biollaz J., Waeber B., Nussberger J., Turini G.A., Brunner H.R., Brunner-Ferber F., Gomez H.J., Otterbein E.S., 1986. Journal of cardiovascular pharmacology, 8 (1) pp. 216-20. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AD1030A96B17]
 
Effets d'une perfusion de facteur natriurétique auriculaire humain chez des volontaires sains [Effects of perfusion of human atrial natriuretic factor in normal volunteers]
Bidiville J., Waeber G., Nussberger J., Biollaz J., Porchet M., Waeber B., Brunner H.R., 1986. Schweizerische medizinische Wochenschrift, 116 (49) pp. 1733-5. Peer-reviewed.
[WoS][Pmid][serval:BIB_85F811EAB016]
 
Effets de la perfusion de facteurs natriurétiques auriculaires synthétiques sur quelques flux régionaux chez le volontaire sain [Effect of synthetic atrial natriuretic factors on various regional blood flows in the healthy subject]
Biollaz J., Waeber G., Jaggi C., Waeber B., Nussberger J., Brunner H.R., 1986. Archives des maladies du coeur et des vaisseaux, 79 (6) pp. 961-6. Peer-reviewed.
[WoS][Pmid][serval:BIB_AF5E39915936]
 
Four-hour infusions of synthetic atrial natriuretic peptide in normal volunteers.
Biollaz J., Nussberger J., Porchet M., Brunner-Ferber F., Otterbein E.S., Gomez H., Waeber B., Brunner H.R., 1986. Hypertension, 8 (6 Pt 2) pp. II96-105. Peer-reviewed.
[Pmid][serval:BIB_FD5FE7F08CA4]
 
Hormonal, global, and regional haemodynamic responses to a vascular antagonist of vasopressin in patients with congestive heart failure with and without hyponatraemia.
Nicod P., Biollaz J., Waeber B., Goy J.J., Polikar R., Schlapfer J., Schaller M.D., Turini G.A., Nussberger J., Hofbauer K.G. et al., 1986. British Heart Journal, 56 (5) pp. 433-439.
[WoS][Pmid][serval:BIB_697A580F5B32]
1985
 
Cimetidine inhibition of ethmozine metabolism
Biollaz J., Shaheen O., Wood A. J., 1985/06. Clinical Pharmacology and Therapeutics, 37 (6) pp. 665-8.
[DOI][WoS][Pmid][serval:BIB_891A35B961B0]
 
Sodium chloride-induced partial inhibition in vivo of alpha 2-adrenoceptor agonist function
Kohlmann, O., Jr. , Gavras I., Biollaz J., Biollaz B., Gavras H., 1985/06. Journal of Hypertension, 3 (3) pp. 269-74.
[DOI][WoS][Pmid][serval:BIB_B5163A717E94]
1984
 
Acute cardiovascular effects of two central phenylethanolamine-N-methyl-transferase inhibitors in unanesthetized desoxycorticosterone-salt hypertensive rats
Biollaz B., Biollaz J., Kohlman, O., Jr. , Bresnahan M., Gavras I., Gavras H., 1984/07. European Journal of Pharmacology, 102 (3-4) pp. 515-9.
[DOI][WoS][Pmid][serval:BIB_C3858F32EA76]
 
Blood pressure variability in ambulatory hypertensive patients: effect of beta-blocking agents and/or diuretics
Jacot-des-Combes B., Brunner H. R., Waeber B., Porchet M., Biollaz J., 1984/04. Journal of Cardiovascular Pharmacology, 6 (2) pp. 263-6.
[DOI][WoS][Pmid][serval:BIB_6B5909C5180A]
 
Ambulatory blood pressure recording to identify hypertensive patients who truly need therapy
Waeber B., Jacot des Combes B., Porchet M., Biollaz J., Schaller M. D., Brunner H. R., 1984. Journal of Chronic Diseases, 37 (1) pp. 55-7.
[DOI][WoS][Pmid][serval:BIB_A7D41B2CAE56]
1983
 
Traitement de la crise hypertensive par le captopril. [Treatment of hypertensive crisis with captopril]
Biollaz J., Waeber B., Turini G. A., Schaller M. D., Brunner H. R., 1983/12. Schweizerische Medizinische Wochenschrift, 113 (52) pp. 2006-7.
[WoS][Pmid][serval:BIB_BDF348264511]
 
Blood pressure maintenance in awake dehydrated rats: renin, vasopressin, and sympathetic activity
Burnier M., Biollaz J., Brunner D. B., Brunner H. R., 1983/08. American Journal of Physiology. Heart and Circulatory Physiology, 245 (2) pp. H203-9.
[WoS][Pmid][serval:BIB_98C3E458F2EF]
 
Profils et variations de la pression arterielle ambulatoire chez des patients hypertendus traites et non traites. [Profiles and variations of ambulatory arterial pressure in treated and untreated hypertensive patients]
Jacot des Combes B., Waeber B., Porchet M., Biollaz J., Brunner H. R., 1983/03. Schweizerische Medizinische Wochenschrift, 113 (10) pp. 371-2.
[Pmid][serval:BIB_F87764FA2CE3]
 
Alpha and beta adrenoceptor blockade in normotensive and deoxycorticosterone (DOC)-hypertensive rats; plasma vasopressin and vasopressin pressor effect
Burnier M., Biollaz J., Brunner D. B., Gavras H., Brunner H. R., 1983/01. Journal of Pharmacology and Experimental Therapeutics, 224 (1) pp. 222-7.
[WoS][Pmid][serval:BIB_D165F3DEC373]
 
Clinical application of orally active angiotensin converting enzyme inhibitors
Gavras H., Biollaz J., Waeber B., Brunner H. R., Gavras I., 1983. Advances in Experimental Medicine and Biology, 156 (Pt B) pp. 1127-31.
[Pmid][serval:BIB_EBD7EE993C48]
 
Hypertensive crisis treated with orally administered captopril
Biollaz J., Waeber B., Brunner H. R., 1983. European Journal of Clinical Pharmacology, 25 (2) pp. 145-9.
[DOI][WoS][Pmid][serval:BIB_8E240D3DD3B3]
 
The clinical application of converting enzyme inhibitors.
Brunner H.R., Turini G.A., Waeber B., Nussberger J., Biollaz J., 1983. Clinical and experimental hypertension. Part A, Theory and practice, 5 (7-8) pp. 1355-66.
[DOI][WoS][Pmid][serval:BIB_08B716F59DCC]
1982
 
Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade
Biollaz J., Brunner H. R., Gavras I., Waeber B., Gavras H., 1982/12. Journal of Cardiovascular Pharmacology, 4 (6) pp. 966-72.
[DOI][WoS][Pmid][serval:BIB_8A0CF67C5294]
 
Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system
Biollaz J., Schelling J. L., Jacot Des Combes B., Brunner D. B., Desponds G., Brunner H. R., Ulm E. H., Hichens M., Gomez H. J., 1982/09. British Journal of Clinical Pharmacology, 14 (3) pp. 363-8.
[WoS][Pmid][serval:BIB_D9807194974D]
 
Enalapril maleate and a lysine analogue (MK-521): disposition in man
Ulm E. H., Hichens M., Gomez H. J., Till A. E., Hand E., Vassil T. C., Biollaz J., Brunner H. R., Schelling J. L., 1982/09. British Journal of Clinical Pharmacology, 14 (3) pp. 357-62.
[WoS][Pmid][serval:BIB_E80FAA4D7EBB]
 
Escape from mineralocorticoid excess: the role of angiotensin II
Biollaz J., Durr J., Brunner H. R., Porchet M., Gavras H., 1982/06. Journal of Clinical Endocrinology and Metabolism, 54 (6) pp. 1187-93.
[DOI][WoS][Pmid][serval:BIB_9E3D043B6082]
 
Comparison in normal volunteers of three converting enzyme inhibitors: RHC 3659, MK 421 and captopril
Burnier M., Biollaz J., Brunner H. R., Turini G. A., Gavras H., 1982/04. American Journal of Cardiology, 49 (6) pp. 1550-1.
[DOI][WoS][Pmid][serval:BIB_D0D272885C4D]
 
Effects of the new oral angiotensin converting enzyme inhibitor MK-421 in human hypertension
Gavras H., Biollaz J., Waeber B., Brunner H. R., Gavras I., Davies R. O., 1982. Clinical and Experimental Hypertension. Part A, Theory and Practice, 4 (1-2) pp. 303-14.
[DOI][WoS][Pmid][serval:BIB_290E650D9676]
1981
 
Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects
Brunner D. B., Desponds G., Biollaz J., Keller I., Ferber F., Gavras H., Brunner H. R., Schelling J. L., 1981/05. British Journal of Clinical Pharmacology, 11 (5) pp. 461-7.
[WoS][Pmid][serval:BIB_13DC5BD6BEFA]
 
Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I
Biollaz J., Burnier M., Turini G. A., Brunner D. B., Porchet M., Gomez H. J., Jones K. H., Ferber F., Abrams W. B., Gavras H. et al., 1981/05. Clinical Pharmacology and Therapeutics, 29 (5) pp. 665-70.
[DOI][WoS][Pmid][serval:BIB_D12B06E58ADA]
 
Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421".
Gavras H., Biollaz J., Waeber B., Brunner H.R., Gavras I., Davies R.O., 1981. Lancet, 2 (8246) pp. 543-547. Peer-reviewed.
[WoS][Pmid][serval:BIB_E585E8F98667]
 
Effects of the oral angiotensin-converting enzyme inhibitor MK-421 in human hypertension.
Gavras H., Biollaz J., Waeber B., Brunner H.R., Gavras I., Sackel H., Charocopos F., Davies R.O., 1981. Clinical Science, 61 (Suppl. 7) pp. 281s-283s. Peer-reviewed.
[WoS][Pmid][serval:BIB_FF95D8F4D668]
1980
 
Facteurs aggravant l'anemic en hemodialyse chronique: destruction exageree ou pertes? [Factors aggravating the anemia in chronic hemodialysis: destruction or loss?]
Wauters J. P., Biollaz J., Delaloye-Bischof A., Delaloye B., 1980/12. Schweizerische Medizinische Wochenschrift, 110 (49) pp. 1888-90.
[WoS][Pmid][serval:BIB_5D85EA4EC134]
1979
 
The renal effects of clonidine in unanesthetized rats
Biollaz J., Roch-Ramel F., Kirchertz E. J., Atkinson J., Peters-Haefeli L., 1979/10. European Journal of Pharmacology, 58 (4) pp. 407-18.
[DOI][WoS][Pmid][serval:BIB_0D4795CEE57B]
 
Renal function tests in experimental toxicity studies
Diezi J., Biollaz J., 1979. Pharmacology and Therapeutics. Part B, General and Systematic Pharmacology, 5 (1-3) pp. 135-45.
[DOI][WoS][Pmid][serval:BIB_DA5B8D0E57D2]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University